Thus, TRPM2 elevation occurs not only in EGFRm NSCLC cell lines with acquired resistance to osimertinib, but also in the majority of EGFRm NSCLC tissues relapsed from EGFR‐TKI treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.